Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse

a selective chloride channel and modulator technology, applied in the direction of biocide, drug composition, peptide/protein ingredients, etc., can solve the problems of increasing the compulsion to take more drugs, depressed motivation and mood, and depressed mood, so as to reduce cravings and withdrawal symptoms, and control cravings

Inactive Publication Date: 2005-09-01
HIGHBRIDGE INT LLC AS AGENT HIGHBRIDGE CAPITAL MANAGEMENT
View PDF27 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0026] It is another object of the present invention to provide for methods and protocols that reduce cravings and withdrawal symptoms from addiction to alcohol and / or psychostimulants that includes administration, to a patient in need of said treatment, of a therapeutically effective quantity of a compound that directly or indirectly selectively modulates chloride channel activity, administered in multiple doses at a predetermined rate, until said therapeutically effective quantity administration reduces cravings and withdrawal symptoms from addiction to alcohol and / or psychostimulants.
[0027] It is another object of the present invention to provide a methodology for controlling cravings, reducing withdrawal symptoms and treating addiction to alcohol and / or psychostimulants. It is yet another object of the present invention to administer a compound that directly or indirectly selectively modulates chloride channel activity, such as, but not limited to flumazenil, in a therapeutically effective quantity so as to control cravings and withdrawal symptoms. In addition, the methodology according to the invention also results in improved cognitive function.
[0028] It is yet another object of the present invention to provide a methodology and protocol for reducing patient dropout rates for those patients undergoing treatment for alcohol and / or psychostimulant addiction. The invention includes the administration of a compound that directly or indirectly selectively modulates chloride channel activity in a therapeutically effective quantity resulting in higher patient recovery rates compared to conventional treatments. This, in turn, results in lower patient dropout rates.
[0029] Optionally, it is another object of the present invention to provide for administration of therapeutically effective amounts of flumazenil in multiple doses at a predetermined rate which results in significantly lower patient dropout rates and fewer side effects in the patient.

Problems solved by technology

Alcohol and stimulant substance abuse disorders have a devastating economic and societal impact on the United States population.
First, a reduction in the ability of natural rewards to activate the reward pathways leads to depressed motivation and mood, and increased compulsion to take more drugs.
For many individuals, an innate neurochemical anomaly renders them susceptible to substance dependency or addictive behavior, even before any long-term effects of alcohol on neurological processing are evident.
It is clear, however, that excessive drinking over time can lead to the impairment of brain function and result in structural brain changes in frontal and prefrontal areas of the brain, which are associated with cognition.
Repeated exposure results in cross-tolerance and cross-dependence between alcohol and benzodiazepines.
Consequently, an alcohol dependent person experiences stress, a down regulation of GABAA and an increase in the severity of withdrawal symptoms when he or she attempts to withdraw.
Therefore, when an alcoholic attempts to initiate abstinence or stop consuming alcohol, he or she may experience withdrawal symptoms, including cravings, which often result in a failure to stop consuming alcohol.
In some cases, withdrawal symptoms may be more severe and result in complications, including seizures, hallucinosis, hallucinations with severe tremors (or “delirium tremens”, DTs) and difficulty regulating body temperature.
These complications may often be fatal.
Stimulants affect a number of neurological circuits, including dopaminergic, beta-adrenergic, serotonergic, glutamatergic, GABAergic circuits, and ultimately results in impaired dopamine function.
GABAA functionality is eventually impaired.
As dosing increases, a person starts to experience tremors, emotional instability, restlessness, irritability, and feelings of paranoia and panic.
A return of “normal” mood and the ability to experience pleasure may take a significant amount of time due to the depletion or modification of neurotransmitters.
Alcohol and psychostimulant substance abuse are often associated with changes in food selection and intake that lead to calorie and protein malnutrition and disruption of energy expenditure.
The resulting malnutrition is related to deficient food intake, malabsorption, increased protein turnover, liver disease, intensity of drug addiction, anorexia, and poor food and drink consumption.
Furthermore, the disturbance of social and familial links can itself result in poor nutrition.
Malnutrition, in turn, is associated with impairment of immune function.
Detoxification can take 3-5 days, involves sedation with potentially dependence forming drugs, and is generally uncomfortable for the patient.
These treatments, however, have limited success and have high dropout rates.
Side effects of these drugs may include impairment of psychomotor performance; amnesia; euphoria; dependence; and rebound (i.e., the return of symptoms) transiently worse than before treatment, upon discontinuation of the drug.
Moreover, Gerra et al. do not present data concerning the evaluation of dependency or craving either before or after administration of the drug.
Most importantly, however, Gerra et al. discloses the administration of very small quantities of flumazenil over long periods of time, which was not particularly effective at treating alcohol dependency.
The results obtained after the administration of flumazenil were not completely satisfactory since in some cases, there was an immediate worsening of the withdrawal symptoms, especially of sweats and anxiety.
Since flumazenil is metabolized and eliminated very rapidly, the IV administration of a relatively high dose of flumazenil in a single dose of 2 mg, for 1 minute, has several disadvantages since such dosing triggers undesired side effects, and the bulk of flumazenil administered yields no pharmacological response and results in unnecessary expense.
Moreover, the results obtained by Gerra et al. and by Nutt et al. are not conclusive since in some cases, no significant changes were observed in either the blood pressure or the heart rate of patients after the administration of flumazenil, an immediate worsening of the withdrawal symptoms was observed, especially sweats and anxiety, and the tests were performed using a very small non-representative patient sample.
Doses, however, were provided for rat models and cannot be readily translated to human dosage levels.
However, all disclosed uses of flumazenil in the treatment of alcohol withdrawal and addiction have relied on either the single administration of large quantities of flumazenil or on-going administrations of very low quantities of flumazenil over long periods of time.
Moreover, the disclosed administrative regimens has not applied the use of flumazenil, or a class of compounds represented by flumazenil, for treating psychostimulant substance abuse at all.
Furthermore, conventional treatments for alcohol and / or psychostimulant dependency have had limited success and often have undesirable side effects.
In addition, conventional treatments for controlling withdrawal symptoms and cravings for alcohol and / or psychostimulants have had limited success and often have undesirable side effects.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
  • Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
  • Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse

Examples

Experimental program
Comparison scheme
Effect test

example 1

Treatment of Patients With Flumazenil in Multiple Dosages at Predetermined Time Periods

1.1 Experimental Protocol

[0252] 64 alcoholics (51 males and 13 females) voluntarily entered a treatment program to discontinue the use of alcohol. The patients were provided the appropriate information and the corresponding informed consent form was obtained from them. The patients were warned not to drink alcohol the morning on which the treatment was to be carried out to enable better evaluation of the withdrawal symptoms. Table 14 summarizes the characteristics of the patients treated associated with alcohol use.

TABLE 14Characteristics of Patients Associated withAlcohol Use (note: 85% consumed alcohol daily and 39.1%consumed benzodiazepines daily).STANDARDMINI-MAXI-CHARACTERISTICSMEANDEVIATIONMUMMUMAGE (YEARS)42.710.22075AGE AT BEGINNING24.610.2671OF DAILY ALCOHOLUSE (YEARS)DAILY UNITS OF24.915.4473ALCOHOL INTAKEGAMMA-GLUTAMYL159.1227.2121.230TRANSPEPTIDASE(GGT)CORPUSCULAR97.86.472111VOLUM...

example 2

Improved Methodology for the Administration of Flumazenil to Treat Alcohol Dependency

[0276] Before starting the protocol, the patients underwent a complete medical and psychological examination. The monitoring of the patients included a complete blood count, a biochemical profile [creatinine, glucose, blood urea nitrogen (BUN), cholesterol (HDL and LDL), triglycerides, alkaline phosphatase, LDH (lactic dehydrogenase) and total proteins], hepatic function tests [GOT, GPT, GGT, bilirubin), electrocardiogram and, if need be, pregnancy test and x-ray examination. The exclusion criteria applied included acute or uncompensated illnesses, as well as the taking of any drug contraindicated with flumazenil. No patient was excluded after the pre-admission interview and the tests performed.

[0277] In addition, patients diagnosed with a psychotic disorder received anti-psychotic medication. Patients diagnosed with arterial hypertension are prescribed the appropriate medication or instructed to ...

example 3

Improved Methodology for the Administration of Flumazenil to Treat Alcohol Dependency

[0281] In accordance with this embodiment of the present invention, as related to such example, a protocol for the treatment of alcohol cravings is described in the table below:

Day 3 -TimeAdmission DayDay 2DischargePre-ProcedureAtaraxAtaraxFortified(AM)(sedative) -(sedative) -Vitamin B50 mg (1-2 hour50 mg (1-2 hourcomplex.pre-procedure).pre-procedure).May repeat withMay repeat withProtein25 mg for25 mg forDrink.anxiety ifanxiety ifneeded.needed.FortifiedFortifiedVitamin BVitamin Bcomplex.complex.Protein Drink.Protein Drink.ProcedureFlumazenil 2 mgFlumazenil 2 mgper dayper dayPost-ProcedureAtarax 50 mg. atAtarax 50 mg. at(PM)bedtime maybedtime mayrepeat with 25 mg.repeat with 25 mg.as neededas neededfor sleep.for sleep.

[0282] At discharge, the following may be administered: disulfiram 250 mg., daily for six months; glutamic acid, 500 mg., once daily for one day, twice daily for one day, then three...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Massaaaaaaaaaa
Timeaaaaaaaaaa
Mass flow rateaaaaaaaaaa
Login to View More

Abstract

The invention relates to methods of and treatments for using pharmaceutical compositions from a class of compounds that directly or indirectly selectively modulates GABAA chloride channel activity to treat alcohol and / or stimulant substance abuse. The present invention also relates to methods of, and protocols for, relieving symptoms associated with alcohol and / or stimulant substance abuse in a comprehensive treatment plan. More specifically, the present invention relates to the use of a selective chloride channel modulator, such as flumazenil, to treat alcohol and / or psychostimulant dependency, the withdrawal symptoms associated therewith, and the cravings associated therewith.

Description

CROSS REFERENCE [0001] The present invention is a continuation in part of U.S. patent application Ser. No. 10 / 621,229, entitled “Use of flumazenil in the production of a drug for the treatment of alcohol dependency”, filed on Jul. 15, 2003.FIELD OF THE INVENTION [0002] The invention relates to methods of, and methodologies for, using pharmaceutical compositions from a class of compounds that directly or indirectly selectively modulates GABAA chloride channel activity to treat alcohol and / or psychostimulant substance abuse, including, but not limited to, the various physical and psychological states that manifest an individual's impaired control over substance use, addiction, continued substance use despite harm, compulsive substance use, cravings, psychological dependence, physical dependence, tolerance, a maladaptive pattern of substance use, preoccupation with substance use, and / or the prevalence of withdrawal symptoms upon cessation of use. The present invention also relates to m...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/195A61K31/551
CPCA61K31/137A61K31/195A61K31/551A61K31/5517A61K45/06A61K2300/00A61P25/30A61P25/32A61P25/36A61P43/00
Inventor LEGARDA IBANEZ, JUAN JOSE
Owner HIGHBRIDGE INT LLC AS AGENT HIGHBRIDGE CAPITAL MANAGEMENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products